Cancer immunotherapy: From the lab to clinical applications - Potential impact on cancer centres' organisation

Linda Cairns; Sandrine Aspeslagh; Andrea Anichini; Jon Amund Kyte; Christian Blank; Paolo A Ascierto; Nicolle Rekers; Eivind Per thor Straten; Ahmad Awada

doi:10.3332/ecancer.2016.691

Cancer immunotherapy: From the lab to clinical applications - Potential impact on cancer centres' organisation

Linda Cairns^*, Sandrine Aspeslagh, Andrea Anichini, Jon Amund Kyte, Christian Blank, Paolo A Ascierto, Nicolle Rekers, Eivind Per thor Straten, Ahmad Awada

^*Corresponding author for this work

73 Downloads (Pure)

Abstract

This report covers the Immunotherapy sessions of the 2016 Organisation of European Cancer Institutes (OECI) Oncology Days meeting, which was held on 15th-17th June 2016 in Brussels, Belgium. Immunotherapy is a potential cancer treatment that uses an individual's immune system to fight the tumour. In recent years significant advances have been made in this field in the treatment of several advanced cancers. Cancer immunotherapies include monoclonal antibodies that are designed to attack a very specific part of the cancer cell and immune checkpoint inhibitors which are molecules that stimulate or block the inhibition of the immune system. Other cancer immunotherapies include vaccines and T cell infusions. This report will summarise some of the research that is going on in this field and will give us an update on where we are at present.

Original language	English
Article number	691
Journal	ecancermedicalscience
Volume	10
DOIs	https://doi.org/10.3332/ecancer.2016.691
Publication status	Published - 9 Nov 2016

Keywords

Cancer vaccines
Immunotherapy
Monoclonal antibodies

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3332/ecancer.2016.691Licence: CC BY

Cancer immunotherapy: from the lab to clinical applications—Potential impact on cancer centres’ organisationFinal published version, 257 KBLicence: CC BY

Cite this

@article{5a733a10de3d440db550b225c5c38a72,

title = "Cancer immunotherapy: From the lab to clinical applications - Potential impact on cancer centres' organisation",

abstract = "This report covers the Immunotherapy sessions of the 2016 Organisation of European Cancer Institutes (OECI) Oncology Days meeting, which was held on 15th-17th June 2016 in Brussels, Belgium. Immunotherapy is a potential cancer treatment that uses an individual's immune system to fight the tumour. In recent years significant advances have been made in this field in the treatment of several advanced cancers. Cancer immunotherapies include monoclonal antibodies that are designed to attack a very specific part of the cancer cell and immune checkpoint inhibitors which are molecules that stimulate or block the inhibition of the immune system. Other cancer immunotherapies include vaccines and T cell infusions. This report will summarise some of the research that is going on in this field and will give us an update on where we are at present.",

keywords = "Cancer vaccines, Immunotherapy, Monoclonal antibodies",

author = "Linda Cairns and Sandrine Aspeslagh and Andrea Anichini and Kyte, {Jon Amund} and Christian Blank and Ascierto, {Paolo A} and Nicolle Rekers and {thor Straten}, {Eivind Per} and Ahmad Awada",

year = "2016",

month = nov,

day = "9",

doi = "10.3332/ecancer.2016.691",

language = "English",

volume = "10",

journal = "ecancermedicalscience",

issn = "1754-6605",

publisher = "Cancer Intellilgence",

}

TY - JOUR

T1 - Cancer immunotherapy

T2 - From the lab to clinical applications - Potential impact on cancer centres' organisation

AU - Cairns, Linda

AU - Aspeslagh, Sandrine

AU - Anichini, Andrea

AU - Kyte, Jon Amund

AU - Blank, Christian

AU - Ascierto, Paolo A

AU - Rekers, Nicolle

AU - thor Straten, Eivind Per

AU - Awada, Ahmad

PY - 2016/11/9

Y1 - 2016/11/9

N2 - This report covers the Immunotherapy sessions of the 2016 Organisation of European Cancer Institutes (OECI) Oncology Days meeting, which was held on 15th-17th June 2016 in Brussels, Belgium. Immunotherapy is a potential cancer treatment that uses an individual's immune system to fight the tumour. In recent years significant advances have been made in this field in the treatment of several advanced cancers. Cancer immunotherapies include monoclonal antibodies that are designed to attack a very specific part of the cancer cell and immune checkpoint inhibitors which are molecules that stimulate or block the inhibition of the immune system. Other cancer immunotherapies include vaccines and T cell infusions. This report will summarise some of the research that is going on in this field and will give us an update on where we are at present.

AB - This report covers the Immunotherapy sessions of the 2016 Organisation of European Cancer Institutes (OECI) Oncology Days meeting, which was held on 15th-17th June 2016 in Brussels, Belgium. Immunotherapy is a potential cancer treatment that uses an individual's immune system to fight the tumour. In recent years significant advances have been made in this field in the treatment of several advanced cancers. Cancer immunotherapies include monoclonal antibodies that are designed to attack a very specific part of the cancer cell and immune checkpoint inhibitors which are molecules that stimulate or block the inhibition of the immune system. Other cancer immunotherapies include vaccines and T cell infusions. This report will summarise some of the research that is going on in this field and will give us an update on where we are at present.

KW - Cancer vaccines

KW - Immunotherapy

KW - Monoclonal antibodies

U2 - 10.3332/ecancer.2016.691

DO - 10.3332/ecancer.2016.691

M3 - Journal article

C2 - 27994647

AN - SCOPUS:84996482869

SN - 1754-6605

VL - 10

JO - ecancermedicalscience

JF - ecancermedicalscience

M1 - 691

ER -

Cancer immunotherapy: From the lab to clinical applications - Potential impact on cancer centres' organisation

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this